ONTARGET: Does Dual Blockade of the Renin-Angiotensin System Provide More Effective Cardiovascular and Renal Protection in Patients at High Cardiovascular Risk?

Aims: The Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET) was a randomized, double-blind trial conducted in 25,620 patients. The aims were to assess whether telmisartan was noninferior to ramipril, and whether combined blockade would result in better cardiovascular protection than ramipril [1]. The primary renal outcome was a composite outcome including death, end-stage renal disease (ESRD), and serum creatinine doubling [2].